Diagnosis and treatment of aluminium bone disease.

Aluminium accumulation in serum and tissues is a well-known complication in patients with chronic renal failure, and retention of the element in bone has been implicated in the pathogenesis of the so-called aluminium-related bone disease (ARBD). Regular serum aluminium monitoring remains mandatory to detect patients and centres at risk for aluminium intoxication. Early recognition of ARBD however requires a desferrioxamine (DFO) test in combination with a serum iPTH measurement. Definite diagnosis of ARBD is made by histological examination of a bone biopsy. Once ARBD has been identified DFO treatment should be initiated and all potential sources of aluminium exposure eliminated. In order to minimize the risk for DFO-related cerebral, auditory and visual side-effects, and siderophore-mediated opportunistic infections the chelator should be used at low doses (5 mg/kg) and administered widely spaced (once weekly) following well-defined strategies of administration.

[1]  Berlyne Gm.  Aluminum toxicity in renal failure. , 1980 .

[2]  J. Boelaert,et al.  Side-effects of desferrioxamine in dialysis patients. , 1993, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[3]  M. D. de Broe,et al.  Measurement of aluminum in serum, blood, urine, and tissues of chronic hemodialyzed patients by use of electrothermal atomic absorption spectrometry. , 1985, Clinical chemistry.

[4]  M. Broe,et al.  The metabolism of aluminum , 1990 .

[5]  M. D. de Broe,et al.  Low-dose (5 mg/kg) desferrioxamine treatment in acutely aluminium-intoxicated haemodialysis patients using two drug administration schedules. , 1996, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[6]  M. D. de Broe,et al.  Use of the low-dose desferrioxamine test to diagnose and differentiate between patients with aluminium-related bone disease, increased risk for aluminium toxicity, or aluminium overload. , 1995, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[7]  M. Ward,et al.  Aluminium Toxicity in Renal Failure , 1983 .

[8]  M. D. de Broe,et al.  Value of serum aluminium monitoring in dialysis patients: a multicentre study. , 1990, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[9]  G. Becker,et al.  Clinical and biochemical features of aluminum-related bone disease. , 1986, Kidney international. Supplement.

[10]  W. Goodman.  Pathophysiologic mechanisms of aluminum toxicity: Aluminum-induced bone disease , 1990 .

[11]  S. Ott,et al.  Changes in bone histology after treatment with desferrioxamine. , 1986, Kidney international. Supplement.

[12]  M. D. de Broe,et al.  Cela n'arrive qu'aux autres (aluminium intoxication only happens in the other nephrologist's dialysis centre) , 1994, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[13]  J. Coburn,et al.  Aluminum and renal failure , 2011, Developments in Nephrology.

[14]  M. D. de Broe,et al.  Pharmacokinetics of aluminoxamine and ferrioxamine and dose finding of desferrioxamine in haemodialysis patients. , 1992, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[15]  M. D. de Broe,et al.  Removal of aluminoxamine and ferrioxamine by charcoal hemoperfusion and hemodialysis. , 1992, Kidney international.